Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490009 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
A Phase 2 study of Lymphoma, sponsored by Susan Knox.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00490009 is a Phase 2 study of Lymphoma that has completed, run by Susan Knox. The registered enrollment target is 9 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00490009, a Phase 2 study of Lymphoma, has completed, sponsored by Susan Knox.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Diphenhydramine
- DRUG Bexxar
- DRUG Potassium Iodide (KI)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490009
The ClinicalTrials.gov registry entry for NCT00490009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The listed sponsor is Susan Knox, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Acetaminophen is the first listed.
NCT00490009 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00490009 about?
NCT00490009 is a clinical study titled "Phase 2 Study of Bexxar in Relapsed/Refractory DLCL". The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
What is the current status of trial NCT00490009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-09. Estimated completion is 2013-06.
What conditions does trial NCT00490009 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00490009?
The interventions under investigation include: Acetaminophen (DRUG), Diphenhydramine (DRUG), Bexxar (DRUG), Potassium Iodide (KI) (DRUG).
Who is sponsoring clinical trial NCT00490009?
This trial is sponsored by Susan Knox, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00490009 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.